Kymera Therapeutics (KYMR) PT Raised to $152 at Stifel on Ph2b BROADEN2 Data

September 21, 2026 4:34 PM

Stifel analyst Alex Thompson raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $152.00 (from $132.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found